Please take the time to go through our Congress Report with highlights from this year’s IASLC World Congress of Lung Cancer, which took place from 7-9 September in Barcelona. You will see rapid growing evidence consolidating immunotherapy as the standard for most patients with Non-Small-Cell Lung Cancer – and now also with Small-Cell Lung Cancer, the first good news in decades for the latter.
There’s news in early detection and treatment tailoring, with biomarkers increasingly identified (even though the various forms of PD-L1 scoring remain today the essential ones). Patterns of resistance may be countered with targeting agents - and, who knows, in the future lung cancer patients might be efficiently treated with CAR-T cell therapy.
Our confidence in tre...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Siponimod delays time to wheelchair Next Article
Promising Phase 1 Results of Novel Kras-inhibitor in NSCLC »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.